Evidence map›Paper›PMID 33160934›Full record

ReviewClinical lymphoma, myeloma & leukemia2021

Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma.

Samer A Al-Hadidi, Hubert H Chuang, Roberto N Miranda, Hun Ju Lee

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical lymphoma, myeloma & leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Samer A Al-HadidiDepartment of Hematology and Oncology, Baylor College of Medicine, Houston, TX; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Hubert H ChuangDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Roberto N MirandaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Hun Ju LeeDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: hunlee@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Training In Cell and Gene TherapyT32HL092332 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI MALCOLM K. BRENNER, Bruno Di Stefano · 2008 to 2026
$6.9M
NHLBI NIH HHS T32 HL092332
6 · The paper itself

Abstract

The majority of patients with classical Hodgkin lymphoma (cHL) may be cured, but for patients with relapsed or refractory (R/R) cHL, the prognosis is unfavorable. Immune dysfunction is a significant contributor of relapse and a hallmark of cHL; in particular, the immune system is unable to eradicate lymphoma cells that overexpress immune checkpoint proteins. The blocking of this mechanism used by lymphoma cells to evade the immune system has resulted in clinical benefits. Use of checkpoint inhibitors (CPIs) in R/R cHL is associated with high response rates and an acceptable adverse effects profile. There is growing interest in combining chemotherapy with CPIs in frontline therapy of cHL treatment to improve relapse rates without significant additive toxicity. In this review, we discuss the current evidence supporting CPI use in R/R cHL and maintenance therapy. We present emerging CPI data in frontline adult cHL and assess its role in the elderly. In addition, we discuss critical immune-related toxicities and their management, and elaborate on the challenges of monitoring response and minimal residual disease as tools for maximizing efficacy by limiting toxicity.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmHodgkin DiseaseHumansImmune Checkpoint InhibitorsMaintenance ChemotherapyNeoplasm Recurrence, LocalNeoplasm, ResidualPrognosisProgrammed Cell Death 1 ReceptorProgression-Free SurvivalRandomized Controlled Trials as TopicImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorCheckpoint inhibitorsClassic Hodgkin lymphomaNivolumabPD-1 inhibitionPembrolizumab

Identifiers

PMID33160934
PMCPMC7878303
OpenAlexW3091545794

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.